Bayer's Factory Floor, Lab Bench and Courtroom Are Telling Three Different Stories
Published on 10/24/2026 at 08:40 | Editorial boerse-global.de
Bayer has spent October stacking up announcements that pull in different directions — a multibillion-dollar manufacturing commitment, a regulatory milestone for its kidney drug, a gene-therapy research slot in Hamburg and an unresolved legal overhang. None of them is a sales figure, and that distinction matters more than any single headline.
A $2.2 Billion Bet on Ohio
On October 2, the German group unveiled plans to invest 2.2 billion US dollars in a new pharmaceutical production site in New Albany, Ohio. Around 600 new jobs are expected to follow. The move is a capacity decision, not a revenue event: it describes where Bayer intends to make medicines, not what it will earn from them.
Kerendia's Application Moves Forward
Roughly two weeks earlier, the US Food and Drug Administration accepted Bayer's supplemental application for finerenone, marketed as Kerendia, in chronic kidney disease without diabetes. The filing rests on positive Phase III results from the FIND-CKD trial. Acceptance is a procedural step, not an approval — the additional indication has not yet been cleared, and investors should not read it as an already-opened market.
Those two developments sit on separate tracks. One concerns production capacity, the other the potential uses of a single compound. Neither can be booked as incremental revenue today.
Should investors sell immediately? Or is it worth buying Bayer?
Kidney Data Land at ASN
The clinical picture sharpened just over a week ago, when Bayer presented new subgroup analyses from FIND-CKD as late-breaking data at ASN Kidney Week 2026. The analyses showed consistent effects of finerenone on proteinuria and on loss of kidney function across patient groups with chronic kidney disease but without diabetes.
AskBio Takes the Podium in Hamburg
Away from the clinic, Bayer's gene-therapy unit AskBio will present five posters at the European Society of Gene and Cell Therapy congress, running from October 27 to 30, 2026, in Hamburg. The contributions, announced on Thursday, focus on advances in AAV manufacturing technologies — a research accent that sits well apart from the finerenone data already in circulation.
The distinction is worth spelling out: these are technological presentations, not fresh evidence of clinical efficacy. They carry a fixed date for further technical disclosure but say nothing directly about revenue or profit. What actually gets shown in Hamburg will be the thing to watch.
UBS Stays Positive
Analysts at UBS kept Bayer at "Buy" on October 15 with a price target of 62 euros. The house pointed to continuing trends in Crop Science for 2026 and 2027 as well as momentum in Pharma. The call rests on more than the drug business alone — and it remains an analyst assessment, not a promise of future results.
Bayer at a turning point? This analysis reveals what investors need to know now.
Legal Clouds and the November 3 Test
Weighing on the picture are persistent legal uncertainties. According to media reports, Wednesday's ruling on the glyphosate settlement and the approaching quarterly figures were possible catalysts for the shares. The open settlement thus remains a valuation factor in its own right, running alongside the scientific news flow.
Bayer publishes its third-quarter 2026 interim report on November 3, 2026, accompanied by an investor video call and a media update. Until then, the AskBio congress offers a concrete scientific date, while the Ohio investment and the finerenone filing provide reference points for assessing the pharmaceutical business. What they do not do is pre-empt the numbers — the gap between announced capacity, regulatory progress and reported performance is where the real test lies.
Ad
Bayer Stock: New Analysis - 24 October
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
